| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Nong, C Newton, H Friedman, T W Klei. CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. Advances in experimental medicine and biology. vol 493. 2002-05-20. PMID:11727770. |
marijuana cannabinoid receptors (cbr), cb1 and cb2, are g protein-coupled receptors reported to be expressed in brain as well as cells of the periphery. |
2002-05-20 |
2023-08-12 |
human |
| Francisco Molina-Holgado, Eduardo Molina-Holgado, Carmen Guaza, Nancy J Rothwel. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. Journal of neuroscience research. vol 67. issue 6. 2002-04-09. PMID:11891798. |
role of cb1 and cb2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. |
2002-04-09 |
2023-08-12 |
mouse |
| Francisco Molina-Holgado, Eduardo Molina-Holgado, Carmen Guaza, Nancy J Rothwel. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. Journal of neuroscience research. vol 67. issue 6. 2002-04-09. PMID:11891798. |
in contrast, coincubation with the cb2 receptor antagonist sr-144528 (1 microm) abolished the inhibitory effects of the endogenous cannabinoid anandamide on lps-induced no release, although this may reflect nonspecific effects of this ligand or cannabinoid actions through atypical receptors of anandamide. |
2002-04-09 |
2023-08-12 |
mouse |
| Claire M Williams, Tim C Kirkha. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacology, biochemistry, and behavior. vol 71. issue 1-2. 2002-04-05. PMID:11812541. |
presatiated adult male lister hooded rats received oral administration of the exogenous cannabinoid delta-9-tetrahydrocannabinol (delta(9)-thc; 1.0 mg/kg) in combination with subcutaneous injection of either the cannabinoid cb1 antagonist n-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (sr141716; 0, 0.05, 0.1, 0.5 or 1.0 mg/kg), the cb2 antagonist n-[(1s)-endo-1,3,3-trimethyl bicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (sr144528; 0, 0.05, 0.1, 0.5 or 1.0 mg/kg), the general opioid antagonist naloxone (0.1, 0.5, 1.0 or 5.0 mg/kg) or the 5-ht agonist dexfenfluramine (0.05, 0.1, 0.5, 1.0 or 5.0 mg/kg). |
2002-04-05 |
2023-08-12 |
rat |
| N A Darman. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. European journal of pharmacology. vol 430. issue 1. 2002-01-03. PMID:11698062. |
)-induced vomiting were reversed by nonemetic subcutaneous doses (0, 0.25, 0.5 and 1 mg/kg) of the cannabinoid cb1 receptor antagonist/inverse agonist sr 141716a [n-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide] (id50=0.27 and 0.47 mg/kg, respectively) but not by a 5-mg/kg dose of the cannabinoid cb2 receptor antagonist sr 144528 [n-[(1s)-endo-1,3,3-trimethylbicyclo [2.2.1] heptan-2-yl]5-(4-chloro-3-methylphenyl)-1-(4-methybenzyl) pyrazole-3-carboxamide]. |
2002-01-03 |
2023-08-12 |
Not clear |
| W Ponti, T Rubino, M Bardotti, G Poli, D Parolar. Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages. Veterinary immunology and immunopathology. vol 82. issue 3-4. 2001-12-17. PMID:11587735. |
both cannabinoid receptors, cb1 and cb2, were involved in this process, since the inhibition was reversed by selective cannabinoid antagonists for both of these receptors. |
2001-12-17 |
2023-08-12 |
human |
| C Bartocci, M G Evandri, P Tucci, P Boll. Interactions between A-9THC and capsaicin on isolated lamb bladder detrusor. Farmaco (Societa chimica italiana : 1989). vol 56. issue 5-7. 2001-12-13. PMID:11482756. |
it has been reported that cannabinoids can inhibit the release of cgrp by stimulation of cb1 and cb2 cannabinoid receptors. |
2001-12-13 |
2023-08-12 |
Not clear |
| Philip T Malan, Mohab M Ibrahim, Hongfeng Deng, Qian Liu, Heriberto P Mata, Todd Vanderah, Frank Porreca, Alexandros Makriyanni. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. vol 93. issue 3. 2001-12-04. PMID:11514083. |
cb2 cannabinoid receptor-mediated peripheral antinociception. |
2001-12-04 |
2023-08-12 |
Not clear |
| A Calignano, G La Rana, D Piomell. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. European journal of pharmacology. vol 419. issue 2-3. 2001-11-01. PMID:11426841. |
the antinociceptive effects of palmitylethanolamide were prevented by the cannabinoid cb2 receptor antagonist sr144528 [n-([1s]-endo-1.3.3-trimethylbicyclo[2.3.1]heptan-2-yl)-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide], not by the cannabinoid cb1 receptor antagonist sr141716a [n-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide x hcl]. |
2001-11-01 |
2023-08-12 |
mouse |
| A Calignano, G La Rana, D Piomell. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. European journal of pharmacology. vol 419. issue 2-3. 2001-11-01. PMID:11426841. |
these effects were prevented by the cannabinoid cb1 receptor antagonist sr141716a, not the cannabinoid cb2 receptor antagonist sr141716a. |
2001-11-01 |
2023-08-12 |
mouse |
| Y Kobayashi, S Arai, K Waku, T Sugiur. Activation by 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, of p42/44 mitogen-activated protein kinase in HL-60 cells. Journal of biochemistry. vol 129. issue 5. 2001-10-04. PMID:11328586. |
the addition of sr144528, a cannabinoid cb2 receptor-specific antagonist, to the cells prior to the addition of 2-ag abolished the response induced by 2-ag, indicating that the cb2 receptor is involved in the response. |
2001-10-04 |
2023-08-12 |
Not clear |
| A C Porter, C C Felde. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacology & therapeutics. vol 90. issue 1. 2001-10-04. PMID:11448725. |
delta(9)-thc binds to and activates two known cannabinoid receptors found in mammalian tissue, cb1 and cb2. |
2001-10-04 |
2023-08-12 |
Not clear |
| A Goutopoulos, P Fan, A D Khanolkar, X Q Xie, S Lin, A Makriyanni. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorganic & medicinal chemistry. vol 9. issue 7. 2001-09-20. PMID:11425567. |
stereochemical selectivity of methanandamides for the cb1 and cb2 cannabinoid receptors and their metabolic stability. |
2001-09-20 |
2023-08-12 |
Not clear |
| A Goutopoulos, P Fan, A D Khanolkar, X Q Xie, S Lin, A Makriyanni. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorganic & medicinal chemistry. vol 9. issue 7. 2001-09-20. PMID:11425567. |
several chiral, analogues of the endogenous cannabinoid receptor ligand, arachidonylethanolamide (anandamide), methylated at the 2,1' and 2' positions using asymmetric synthesis were evaluated in order to study (a) stereoselectivity of binding to cb1 and cb2 cannabinoid receptors; and (b) metabolic stability with regard to anandamide amidase. |
2001-09-20 |
2023-08-12 |
Not clear |
| G Esposito, A A Izzo, M Di Rosa, T Iuvon. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. Journal of neurochemistry. vol 78. issue 4. 2001-09-20. PMID:11520904. |
the cannabinoid cb1 receptor antagonist, sr141716a (0.1-100 nm), but not the cannabinoid cb2 receptor antagonist, sr144528 (0.1-100 nm), reduced in a dose-related manner win 55,212-2-and cannabinol-induced inhibition of nitrite production. |
2001-09-20 |
2023-08-12 |
rat |
| D Zhou, Z H Son. CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. Journal of neuroscience research. vol 65. issue 4. 2001-09-13. PMID:11494371. |
using reverse transcription-polymerase chain reaction and immunofluorescence microscopy, the endogenously expressed cb1, but not cb2, cannabinoid receptors were detected in morphologically differentiated n1e-115 cells. |
2001-09-13 |
2023-08-12 |
mouse |
| K R Kozak, J J Prusakiewicz, S W Rowlinson, C Schneider, L J Marnet. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. The Journal of biological chemistry. vol 276. issue 32. 2001-09-06. PMID:11402053. |
the endocannabinoid, 2-arachidonylglycerol (2-ag), is an endogenous ligand for the central (cb1) and peripheral (cb2) cannabinoid receptors and has been shown to be efficiently and selectively oxygenated by cyclooxygenase (cox)-2. |
2001-09-06 |
2023-08-12 |
Not clear |
| Y H Chang, S T Lee, W W Li. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. Journal of cellular biochemistry. vol 81. issue 4. 2001-06-28. PMID:11329626. |
the endogenous cannabinoid, 2-ag, also serves as a substrate for cox-catalyzing pge(2) production, which in turn modulates the action of cb2. |
2001-06-28 |
2023-08-12 |
Not clear |
| M P Germanò, V D'Angelo, M R Mondello, S Pergolizzi, F Capasso, R Capasso, A A Izzo, N Mascolo, R De Pasqual. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn-Schmiedeberg's archives of pharmacology. vol 363. issue 2. 2001-05-03. PMID:11218077. |
the protective effect of win 55,212-2 (1 mg/kg) was counteracted by the cannabinoid cb1 receptor antagonist sr141716a, but not by the cannabinoid cb2 receptor antagonist sr144528. |
2001-05-03 |
2023-08-12 |
rat |
| C Lagneux, D Lamontagn. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. British journal of pharmacology. vol 132. issue 4. 2001-04-26. PMID:11181418. |
some hearts were perfused with either sr 141716a (a cannabinoid cb(1), receptor antagonist 1 microm), sr 144528 (a cb2 receptor anagonist microm), nnla (3 microm) or sodium nitroprusside (1 microm) 5 min before ischaemia and during the ischaemic period. |
2001-04-26 |
2023-08-12 |
rat |